.ANALYSIS HIGHLIGHT.06 August 2024.
A huge randomized measured trial with cisgender girls highlights the problems of obedience to an everyday oral preexposure prevention routine as well as demonstrates that twice-yearly treatment of lenacapavir can maintain efficient HIV prevention amounts over 6 months.